Opioid-Induced Constipation | Treatment Algorithms: Claims Data Analysis | US | 2024

The treatment of opioid-induced constipation (OIC) relies on various prescription medications, including several agents approved for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) and used off-label. The market faces challenges with low drug treatment rates, as many patients opt for over-the-counter (OTC) therapies. As a result, recently approved drugs like Motegrity and Zelnorm struggle to gain market share, while established treatments like Linzess and Movantik maintain use in both newly diagnosed and recently treated patients. Low persistency and compliance rates underscore the need to secure early use in this market.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
• How have Linzess and Motegrity been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of OIC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of OIC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Allergan, Ironwood, Synergy Pharma, Takeda, Mallinckrodt, Alfasigma, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Endo Pharma

Key drugs: Motegrity, Linzess, Trulance, Ibsrela, Relistor, Symproic, Movantik, Amitiza, lubiprostone generic, naloxone, stimulant laxatives, osmotic laxatives, dietary fiber supplements

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.